| Product Code: ETC319655 | Publication Date: Aug 2022 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Shubham Padhi | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
In Australia, the Colistin market is experiencing significant growth, driven by the rising incidence of bacterial infections and the limited availability of effective antibiotic treatments. Colistin, a last-resort antibiotic, is used to treat multidrug-resistant bacterial infections, particularly in healthcare settings. Factors such as increasing prevalence of antibiotic-resistant bacteria, growing elderly population, and rising awareness about infectious diseases are driving market growth. Moreover, efforts to combat antimicrobial resistance and regulatory initiatives to promote prudent antibiotic use are shaping the market landscape in Australia.
The Australia Colistin market is witnessing significant growth, primarily driven by the increasing prevalence of bacterial infections and the rising demand for effective antibiotics. Colistin, a last-resort antibiotic, is used to treat infections caused by multidrug-resistant bacteria, particularly in critical care settings such as hospitals and long-term care facilities. Factors such as the emergence of antibiotic-resistant pathogens, inadequate infection control measures, and the growing burden of healthcare-associated infections are driving market demand. Moreover, regulatory initiatives to promote antimicrobial stewardship and surveillance programs are shaping market dynamics in Australia.
The Australia Colistin Market faces challenges related to antimicrobial resistance, as the overuse or misuse of colistin can contribute to the development of resistant bacterial strains. Regulatory restrictions and guidelines aimed at controlling antibiotic use in both human and veterinary medicine may impact the market`s growth. Additionally, concerns about colistin`s potential adverse effects on human health and the environment may lead to stricter regulations and scrutiny, affecting market demand.
The use of antibiotics such as colistin in Australia is regulated by the Therapeutic Goods Administration (TGA) to ensure safe and responsible use in human and veterinary medicine. Government policies aim to mitigate the development of antibiotic resistance by promoting prudent use practices and monitoring antibiotic consumption in healthcare and agriculture. In the case of colistin, which is considered a last-resort antibiotic, strict regulations govern its prescription and distribution to prevent misuse and preserve its effectiveness. Additionally, initiatives addressing antimicrobial resistance and promoting alternative treatments drive market dynamics in the colistin market.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Australia Colistin Market Overview |
3.1 Australia Country Macro Economic Indicators |
3.2 Australia Colistin Market Revenues & Volume, 2021 & 2031F |
3.3 Australia Colistin Market - Industry Life Cycle |
3.4 Australia Colistin Market - Porter's Five Forces |
3.5 Australia Colistin Market Revenues & Volume Share, By Product Type, 2021 & 2031F |
3.6 Australia Colistin Market Revenues & Volume Share, By Application, 2021 & 2031F |
4 Australia Colistin Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of multi-drug resistant infections |
4.2.2 Growing awareness about the effectiveness of colistin in treating certain infections |
4.2.3 Rising investments in healthcare infrastructure and facilities in Australia |
4.3 Market Restraints |
4.3.1 Concerns over the development of resistance to colistin |
4.3.2 Stringent regulations and guidelines surrounding the use of colistin |
4.3.3 High cost associated with colistin treatment |
5 Australia Colistin Market Trends |
6 Australia Colistin Market, By Types |
6.1 Australia Colistin Market, By Product Type |
6.1.1 Overview and Analysis |
6.1.2 Australia Colistin Market Revenues & Volume, By Product Type, 2021-2031F |
6.1.3 Australia Colistin Market Revenues & Volume, By API, 2021-2031F |
6.1.4 Australia Colistin Market Revenues & Volume, By Premix, 2021-2031F |
6.1.5 Australia Colistin Market Revenues & Volume, By Others, 2021-2031F |
6.2 Australia Colistin Market, By Application |
6.2.1 Overview and Analysis |
6.2.2 Australia Colistin Market Revenues & Volume, By Pig, 2021-2031F |
6.2.3 Australia Colistin Market Revenues & Volume, By Chicken, 2021-2031F |
6.2.4 Australia Colistin Market Revenues & Volume, By Other, 2021-2031F |
7 Australia Colistin Market Import-Export Trade Statistics |
7.1 Australia Colistin Market Export to Major Countries |
7.2 Australia Colistin Market Imports from Major Countries |
8 Australia Colistin Market Key Performance Indicators |
8.1 Number of reported cases of multi-drug resistant infections in Australia |
8.2 Percentage of healthcare professionals recommending colistin for specific infections |
8.3 Investment trends in research and development of new antibiotics |
8.4 Rate of compliance with regulations on colistin use |
8.5 Average cost of colistin treatment compared to alternative medications |
9 Australia Colistin Market - Opportunity Assessment |
9.1 Australia Colistin Market Opportunity Assessment, By Product Type, 2021 & 2031F |
9.2 Australia Colistin Market Opportunity Assessment, By Application, 2021 & 2031F |
10 Australia Colistin Market - Competitive Landscape |
10.1 Australia Colistin Market Revenue Share, By Companies, 2024 |
10.2 Australia Colistin Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |